TruSight Oncology 500

Assay targeting multiple variant types, including microsatellite instability (MSI) and tumor mutational burden (TMB). Read More...
Select Product(s)

TruSight Oncology 500 DNA Kit (48 samples)

20028213

Price
 
 

TruSight Oncology 500 DNA Kit, For Use with NextSeq (48 samples)

20028214

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, (16 indexes, 24 samples)

20028215

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle, for use with NextSeq (16 indexes, 24 samples)

20028216

Price
 
 

TruSight Oncology 500 DNA Kit plus PierianDx interpretation report (16 indexes, 48 Samples)

20032624

Price
 
 

TruSight Oncology 500 DNA Kit for Use with NextSeq plus PierianDx interpretation report (16 indexes, 48 Samples)

20032625

Price
 
 

TruSight Oncology 500 DNA/RNA Bundle plus PierianDx interpretation report (16 indexes, 24 Samples)

20032626

Price
 
 

TruSight Oncology 500 DNA/RNA Kit for Use with NextSeq plus PierianDx interpretation report (16 indexes, 24 Samples)

20032627

Price
 
 
Services

TruSight Oncology 500 DNA Training

20031667

TruSight Oncology 500 (DNA and RNA) Training

20031668

Product Highlights

TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA* variants implicated in various tumor types.

In addition, it accurately measures key current and emerging immunotherapy biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB).

Save Time, Money, and Samples Through Assay Consolidation

  • Pan-cancer content aligned with key guidelines and clinical trials
  • DNA + RNA* assay targeting 523 genes for assessment of all DNA and RNA variant types, plus MSI and TMB
  • Increase chances of finding a positive biomarker by moving from individual biomarker assays to a single comprehensive NGS assay

Achieve Highly Confident Results

  • Hybrid-capture chemistry combined with sophisticated bioinformatics, leading to high analytical specificity and sensitivity
  • Inclusive of unique molecular indexes (UMIs) for high sensitivity in variant detection
  • Based on proven Illumina SBS sequencing technology
  • Integrated 4-5 day workflow, from sample to final genomic report

Unlock Immuno-Oncology

  • Panel contains immuno-oncology biomarkers MSI and TMB
  • Tumor-only workflow for simplicity and efficiency
  • TMB calling performance similar to whole-exome sequencing (WES) panels
  • Large 1.94 Mb panel and sophisticated algorithm for accurate TMB score
Learn more about TruSight Oncology 500 Family

* The product to evaluate DNA & RNA variants is the TSO500 DNA/RNA bundle.

TruSight Oncology 500 Product Family

All three assays in the family are designed to identify key biomarkers in guidelines and clinical trials.

TruSight Oncology 500 Assay

Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.

TruSight Oncology 500 High-Throughput Assay

Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA Assay

Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.

Purchasing the TruSight Oncology 500 assay for the first time?

Complete the form to receive information about the first-time TruSight Oncology 500 purchase program.

Frequently Purchased Together

Specifications

Analytical Evaluation & Verification Service

The TruSight Oncology 500 Analytical Evaluation Service* is a set of tools intended to guide you in aligning with the latest CAP, AMP, and European standards. We provide recommendations to help you evaluate analytical performance characteristics and integrate products into your workflows.

Learn More
Analytical Evaluation & Verification Service

* This service is available in select countries and regions.

Method-Specific Workflow Example

 

Supporting Data and Figures

 
Detection of currently relevant DNA & RNA* variants for multiple types of cancer. Some key biomarkers include:
Pan-Cancer Biomarkers
NTRK1        NTRK2        NTRK3        MSI        TMB (Emerging)
Lung Melanoma Colon Ovarian Breast Gastric Bladder Myeloid Sarcoma
AKT1 BRAF AKT1 BRAF AKT1 BRAF MSH5 ABL1 ALK
ALK CTNNB1 BRAF BRCA1 AR KIT PMS2 ASX1 APC
BRAF GNA11 HRAS BRCA2 BRCA1 KRAS TSC1 CALR BRAF
DDR2 GNAQ KRAS KRAS BRCA2 MET   CEBPA CDK4
EGFR KIT MET PDGFRA ERBB2 MLH1   ETV6 CTNNB1
ERBB2 MAP2K1 MLH1 FOXL2 FGFR1 PDGFRA   EZH2 ETV6
FGFR1 NF1 MSH2 TP53 FGFR2 TP53   FLT3 EWSR1
FGFR3 NRAS MSH6   PIK3CA     GATA2 FOXO1
KRAS PDGFRA NRAS   PTEN     IDH1 GLI1
MAP2K1 PIK3CA PIK3CA         IDH2 KJT
MET PTEN PMS2         JAK2 MDM2
NRAS TP53 PTEN         KIT MYOD1
PIK3CA   SMAD4         MPL NAB2
PTEN   TP53         NPM1 NF1
RET             RUNX1 PAX3
TP53             SF3B1 PAX7
TMB             SRSF2 PDGFRA
              TP53 PDGFRB
                SDHB
                SDHC
                SMARCB1
                TFE3
                WT1

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on this page.

* The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

Related Products

Based on PierianDx Clinical knowledgebase, as of March 2020